Found: 13
Select item for more details and to access through your institution.
Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study.
- Published in:
- International Journal of Clinical Oncology, 2020, v. 25, n. 4, p. 614, doi. 10.1007/s10147-019-01600-0
- By:
- Publication type:
- Article
Chemoradiotherapy with FOLFOX for esophageal squamous cell cancer with synchronous rectal cancer: Four case reports and a literature review.
- Published in:
- Molecular & Clinical Oncology, 2020, v. 12, n. 1, p. 23, doi. 10.3892/mco.2019.1945
- By:
- Publication type:
- Article
Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival.
- Published in:
- Molecular & Clinical Oncology, 2015, v. 3, n. 5, p. 1053, doi. 10.3892/mco.2015.602
- By:
- Publication type:
- Article
Renal impairment as a risk factor for trifluridine/tipiracil-induced adverse events in metastatic colorectal cancer patients from the REGOTAS study.
- Published in:
- Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-45244-7
- By:
- Publication type:
- Article
Renal impairment as a risk factor for trifluridine/tipiracil-induced adverse events in metastatic colorectal cancer patients from the REGOTAS study.
- Published in:
- Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-45244-7
- By:
- Publication type:
- Article
Clinical Impact of Primary Tumor Location in Metastatic Colorectal Cancer Patients Under Later-Line Regorafenib or Trifluridine/Tipiracil Treatment.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.688709
- By:
- Publication type:
- Article
Survival Benefit of Crossover Administration of Regorafenib and Trifluridine/Tipiracil Hydrochloride for Patients With Metastatic Colorectal Cancer: Exploratory Analysis of a Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study (REGOTAS)
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. N.PAG, doi. 10.3389/fonc.2021.576036
- By:
- Publication type:
- Article
A phase I study of S-1 in combination with nab-paclitaxel in patients with unresectable or recurrent gastric cancer.
- Published in:
- Gastric Cancer, 2017, v. 20, n. 2, p. 350, doi. 10.1007/s10120-016-0614-4
- By:
- Publication type:
- Article
Chemotherapy is effective for stage I gastric cancer in patients with synchronous esophageal cancer.
- Published in:
- Gastric Cancer, 2016, v. 19, n. 2, p. 625, doi. 10.1007/s10120-015-0517-9
- By:
- Publication type:
- Article
Late toxicity in complete response cases after definitive chemoradiotherapy for esophageal squamous cell carcinoma.
- Published in:
- Journal of Gastroenterology, 2006, v. 41, n. 5, p. 425, doi. 10.1007/s00535-006-1771-8
- By:
- Publication type:
- Article
WJOG13219G: The Efficacy and Safety of FOLFOXIRI or Doublet plus Anti-VEGF Therapy in Previously Untreated BRAF<sup>V600E</sup> Mutant Metastatic Colorectal Cancer: A Multi-Institutional Registry-Based Study (BRACELET Study).
- Published in:
- 2022
- By:
- Publication type:
- journal article
A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposure-Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial).
- Published in:
- 2020
- By:
- Publication type:
- journal article
Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer.
- Published in:
- 2018
- By:
- Publication type:
- journal article